Metabolomic Diagnostics

Executive Summary

Metabolomic Diagnostics is an Irish deep-tech company pioneering biomarker-based diagnostic solutions for complex diseases, with a primary focus on pregnancy health. Leveraging advanced LC-MS/MS mass spectrometry and proprietary informatics, the company identifies and translates biomarker panels into clinical assays for personalized pregnancy risk assessments. Founded in 2013 and based in Cork, Metabolomic Diagnostics aims to improve maternal-fetal outcomes by enabling early and accurate detection of conditions such as preeclampsia and preterm birth. The company's technology has the potential to shift prenatal care from reactive to predictive, reducing healthcare costs and improving patient outcomes. Despite being in a competitive landscape with other women's health diagnostics firms, Metabolomic Diagnostics differentiates through its deep expertise in metabolomics and a robust translational research platform. The company is privately held and has not disclosed funding or valuation details, but its technology readiness suggests it is approaching clinical validation milestones. Key upcoming catalysts include the completion of clinical studies for its preeclampsia test, regulatory submissions for CE marking in Europe, and potential strategic partnerships with diagnostic laboratories or pharmaceutical companies interested in pregnancy risk stratification. These events could accelerate commercialization and attract investor interest.

Upcoming Catalysts (preview)

• Q3 2026Completion of Clinical Validation Study for Preeclampsia Test70% success
• Q4 2026CE Mark Submission for Pregnancy Risk Panel60% success
• H1 2027Strategic Partnership with Major Diagnostic Laboratory50% success